6833.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 03:32):

Stats
Today's Volume	56 000.00
Average Volume	130 450
Market Cap	467.56M
EPS	HKD0 ( 2024-05-16 )
Last Dividend	HKD0.00980 ( 2023-05-31 )
Next Dividend	HKD0 ( N/A )
P/E	11.50
ATR14	HKD0 (0.00%)

Sinco Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sinco Pharmaceuticals Financials

Annual	2023
Revenue:	HKD2.54B
Gross Profit:	HKD323.28M (12.73 %)
EPS:	HKD0.0208

FY	2023
Revenue:	HKD2.54B
Gross Profit:	HKD323.28M (12.73 %)
EPS:	HKD0.0208

FY	2022
Revenue:	HKD2.27B
Gross Profit:	HKD305.87M (13.47 %)
EPS:	HKD0.0342

FY	2021
Revenue:	HKD2.02B
Gross Profit:	HKD364.95M (18.03 %)
EPS:	HKD0.0800

Financial Reports:

No articles found.

Sinco Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.00980 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Sinco Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.49 - good (84.91%) | Divividend Growth Potential Score: 6.61 - Stable (32.29%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00330	2016-09-09
Last Dividend	HKD0.00980	2023-05-31
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	HKD0.0131	--
Avg. Dividend % Per Year	0.00%	--
Score	2.49	--
Div. Sustainability Score	8.49
Div.Growth Potential Score	6.61
Div. Directional Score	7.55	--

Next Divdend (Est)
(2029-12-31)

HKD0.0174 Estimate 2.59 %

Dividend Stability

0.21 Very Poor

Dividend Score

2.49

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2378.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
1198.HK	No Dividend Player	2023-07-21	Sporadic	0.00%
0119.HK	Ex Dividend Junior	2023-06-09	Sporadic	0.00%
8371.HK	Ex Dividend Junior	2023-08-03	Annually	0.00%
1830.HK	Ex Dividend Knight	2023-08-16	Annually	0.00%
0728.HK	Ex Dividend Junior	2023-08-23	Annually	0.00%
3316.HK	Ex Dividend Knight	2023-06-20	Annually	0.00%
1346.HK	Ex Dividend Knight	2023-09-12	Annually	0.00%
0259.HK	Ex Dividend Knight	2023-09-26	Annually	0.00%
1982.HK	Ex Dividend Knight	2023-07-06	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0167	1.500	9.67	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0224	1.200	9.25	10.00	[0 - 0.3]
returnOnEquityTTM	0.0687	1.500	-0.348	-0.522	[0.1 - 1]
payoutRatioTTM	0.428	-1.000	5.72	-5.72	[0 - 1]
currentRatioTTM	1.163	0.800	9.18	7.35	[1 - 3]
quickRatioTTM	0.794	0.800	-0.0344	-0.0275	[0.8 - 2.5]
cashRatioTTM	0.355	1.500	9.14	10.00	[0.2 - 2]
debtRatioTTM	0.133	-1.500	7.78	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.159	2.00	9.92	10.00	[0 - 20]
debtEquityRatioTTM	0.400	-1.500	8.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.127	1.000	-1.212	-1.212	[0.2 - 0.8]
operatingProfitMarginTTM	0.0458	1.000	-1.083	-1.083	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.407	1.000	3.29	3.29	[0.2 - 2]
assetTurnoverTTM	1.343	0.800	4.38	3.50	[0.5 - 2]
Total Score				8.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	9.89	1.000	9.10	0	[1 - 100]
returnOnEquityTTM	0.0687	2.50	-0.224	-0.522	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.159	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	1.894	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0.428	1.500	5.72	-5.72	[0 - 1]
pegRatioTTM	9.75	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.139	1.000	9.02	0	[0.1 - 0.5]
Total Score				6.61

Sinco Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sinco Pharmaceuticals

Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.